These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25233825)

  • 1. Reply to: Cardiovascular risk in psoriatic arthritis; should we focus on hypertension and diabetes only? Gkaliagkousi et al.
    Favarato MH; Goldenstein-Schainberg C
    Clin Exp Rheumatol; 2014; 32(6):996. PubMed ID: 25233825
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only?
    Gkaliagkousi E; Gavriilaki E; Aslanidis S; Douma S
    Clin Exp Rheumatol; 2014; 32(6):995. PubMed ID: 25236816
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis.
    Favarato MH; Mease P; Gonçalves CR; Gonçalves Saad C; Sampaio-Barros PD; Goldenstein-Schainberg C
    Clin Exp Rheumatol; 2014; 32(2):182-7. PubMed ID: 24480317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to eLetter by Feldtkeller et al.
    Sørensen J; Hetland ML
    Ann Rheum Dis; 2014 Dec; 73(12):e78. PubMed ID: 25281722
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 May; 74(5):e34. PubMed ID: 25755140
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?
    Boers M
    Ann Rheum Dis; 2015 May; 74(5):e33. PubMed ID: 25714930
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.
    Bergman M; Lundholm A
    Arthritis Res Ther; 2017 Mar; 19(1):63. PubMed ID: 28320454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical challenges faced in real-world management of moderate-to-severe psoriasis: a personal view.
    Cerio R
    G Ital Dermatol Venereol; 2017 Dec; 152(6):551-554. PubMed ID: 28895665
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimization of CVD prevention in psoriatic arthritis.
    Semb AG; Rollefstad S
    Nat Rev Rheumatol; 2018 Jun; 14(6):323-324. PubMed ID: 29686327
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
    Armstrong AW; Gelfand JM; Boehncke WH; Armstrong EJ
    J Rheumatol; 2013 Aug; 40(8):1434-7. PubMed ID: 23908540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
    Cisternas M; Gutiérrez M; Jacobelli S
    Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis.
    Radner H; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1510-1518. PubMed ID: 27998029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe psoriatic dactylitis: when psoriasis involves beyond the skin.
    Husein-ElAhmed H
    Reumatismo; 2016 Sep; 68(2):112-3. PubMed ID: 27608802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-17 inhibition in psoriatic arthritis.
    Helliwell P; Coates L
    Lancet; 2015 Sep; 386(9999):1114-6. PubMed ID: 26135705
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
    Queiro R; Cañete JD
    Clin Rheumatol; 2018 Mar; 37(3):661-666. PubMed ID: 29380165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on psoriatic arthritis.
    Michet CJ
    Int J Dermatol; 2004 Jul; 43(7):479-81. PubMed ID: 15230883
    [No Abstract]   [Full Text] [Related]  

  • 18. Termination of disease modifying antirheumatic drugs in psoriatic arthritis.
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2002 Apr; 29(4):860-1. PubMed ID: 11950038
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy: Secukinumab improves symptoms of psoriatic arthritis.
    Duarte JH
    Nat Rev Rheumatol; 2015 Sep; 11(9):503. PubMed ID: 26168911
    [No Abstract]   [Full Text] [Related]  

  • 20. Early psoriatic arthritis.
    Gladman DD
    Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.